Is DarioHealth Corp. overvalued or undervalued?

As of 11 May 2016, DarioHealth Corp. has moved from a grade of "does not qualify" to "risky." The company is currently overvalued. Key ratios indicate significant financial distress, with a Price to Book Value of 0.42, an EV to EBIT of -0.67, and an EV to EBITDA of -0.80. The company's return on capital employed (ROCE) stands at a troubling -65.26%, and return on equity (ROE) is at -48.75%, highlighting ongoing losses and inefficiencies.
In comparison to peers, DarioHealth Corp. shows a less favorable position; for instance, Clearpoint Neuro, Inc. has a P/E ratio of -15.18 and an EV to EBITDA of -15.26, while Electromed, Inc. is rated attractive with a P/E of 23.50 and an EV to EBITDA of 15.40. The stark contrast in valuation metrics suggests that DarioHealth is not only struggling but also overvalued relative to its peers. Additionally, the company's stock has significantly underperformed against the S&P 500, with a one-year return of -43.37% compared to the index's 10.26%.